Literature DB >> 18177887

Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells.

Yuanyuan Zha1, Ramila Shah, Frederick Locke, Austin Wong, Thomas F Gajewski.   

Abstract

Conditional gene deletion using lineage-specific transgenic expression of Cre has been useful for defining the role of specific gene products in mice in vivo. However, this technology has had limitations for studies of peripheral T cell biology, since the T-lineage promoters commonly used are active early in thymic development. As such, T cell development can be altered by the resulting genetic alterations, thus limiting the interpretation of the data in post-thymic T cell studies. Thus, new strategies are needed to delete targeted genes directly in peripheral T lymphocytes. The availability of transgenic mice expressing the CAR in the T cell compartment enabled testing of Cre-mediated recombination using an adenoviral vector in naïve peripheral T cells in vitro, even without cellular activation. Using Rosa26R reporterxCAR transgenic mice, we describe conditions by which Cre-mediated deletion of targeted genes can be achieved with primary T cells in vitro. These cells can also be adoptively transferred into defined recipient mice for study in vivo. We use conditional PTEN-deficient mice as proof of concept to confirm the value of this technique for deleting a negative regulator of T cell activation. This technology should be broadly applicable for studies of T cell-specific gene deletion to gain understanding of function in the post-thymic T cell compartment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18177887      PMCID: PMC3278801          DOI: 10.1016/j.jim.2007.11.013

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  31 in total

Review 1.  Cre recombinase: the universal reagent for genome tailoring.

Authors:  A Nagy
Journal:  Genesis       Date:  2000-02       Impact factor: 2.487

2.  Episomal segregation of the adenovirus enhancer sequence by conditional genome rearrangement abrogates late viral gene expression.

Authors:  X Wang; W Zeng; M Murakawa; M W Freeman; B Seed
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase.

Authors:  D Jo; A Nashabi; C Doxsee; Q Lin; D Unutmaz; J Chen; H E Ruley
Journal:  Nat Biotechnol       Date:  2001-10       Impact factor: 54.908

4.  Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells.

Authors:  Y Y Wan; R P Leon; R Marks; C M Cham; J Schaack; T F Gajewski; J DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

5.  Staying alive--naïve CD4(+) T cell homeostasis.

Authors:  Jared F Purton; Jonathan Sprent; Charles D Surh
Journal:  Eur J Immunol       Date:  2007-09       Impact factor: 5.532

6.  T cell-specific loss of Pten leads to defects in central and peripheral tolerance.

Authors:  A Suzuki; M T Yamaguchi; T Ohteki; T Sasaki; T Kaisho; Y Kimura; R Yoshida; A Wakeham; T Higuchi; M Fukumoto; T Tsubata; P S Ohashi; S Koyasu; J M Penninger; T Nakano; T W Mak
Journal:  Immunity       Date:  2001-05       Impact factor: 31.745

7.  CD28 is not required for c-Jun N-terminal kinase activation in T cells.

Authors:  F V Rivas; S O'Herrin; T F Gajewski
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

8.  RasGRP is essential for mouse thymocyte differentiation and TCR signaling.

Authors:  N A Dower; S L Stang; D A Bottorff; J O Ebinu; P Dickie; H L Ostergaard; J C Stone
Journal:  Nat Immunol       Date:  2000-10       Impact factor: 25.606

9.  A human CD2 minigene directs CRE-mediated recombination in T cells in vivo.

Authors:  Trevor J Wilson; Helen E Cowdery; Dakang Xu; Ismail Kola; Paul J Hertzog
Journal:  Genesis       Date:  2002-08       Impact factor: 2.487

10.  Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer.

Authors:  Malcolm Logan; James F Martin; Andras Nagy; Corrinne Lobe; Eric N Olson; Clifford J Tabin
Journal:  Genesis       Date:  2002-06       Impact factor: 2.487

View more
  7 in total

1.  Beta-catenin does not regulate memory T cell phenotype.

Authors:  Gregory Driessens; Yan Zheng; Thomas F Gajewski
Journal:  Nat Med       Date:  2010-05       Impact factor: 53.440

2.  Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy.

Authors:  Yan Zheng; Yuanyuan Zha; Robbert M Spaapen; Rebecca Mathew; Kenneth Barr; Albert Bendelac; Thomas F Gajewski
Journal:  Mol Immunol       Date:  2013-03-30       Impact factor: 4.407

3.  Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction.

Authors:  Frederick L Locke; Yuan-yuan Zha; Yan Zheng; Gregory Driessens; Thomas F Gajewski
Journal:  J Immunol       Date:  2013-07-12       Impact factor: 5.422

4.  Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-γ1 phosphorylation.

Authors:  Gregory Driessens; Yan Zheng; Frederick Locke; Judy L Cannon; Fotini Gounari; Thomas F Gajewski
Journal:  J Immunol       Date:  2010-12-13       Impact factor: 5.422

Review 5.  Lymphocyte signaling: beyond knockouts.

Authors:  Alexander Saveliev; Victor L J Tybulewicz
Journal:  Nat Immunol       Date:  2009-03-19       Impact factor: 25.606

6.  TCR Triggering Induces the Formation of Lck-RACK1-Actinin-1 Multiprotein Network Affecting Lck Redistribution.

Authors:  Ondřej Ballek; Jan Valečka; Martina Dobešová; Adéla Broučková; Jasper Manning; Pavel Řehulka; Jiří Stulík; Dominik Filipp
Journal:  Front Immunol       Date:  2016-10-27       Impact factor: 7.561

7.  Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo.

Authors:  Yan Zheng; Yuanyuan Zha; Gregory Driessens; Frederick Locke; Thomas F Gajewski
Journal:  J Exp Med       Date:  2012-11-05       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.